Report on the 9th Interstitial Lung Disease (ILD) Update 2025

Date: 3–5 October 2025

Venue: Auditorium, Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia (UPM) Organised by: Pertubuhan Perubatan Pascasiswzah Institut Perubatan Respiratori (PPPIPR)

In collaboration with: Institut Perubatan Respiratori (IPR)

Supported by: Boehringer Ingelheim

The 9th ILD Update 2025 was successfully conducted from 3rd to 5th October 2025 at the Auditorium, Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia (UPM). The annual educational program continues to serve as a vital platform to enhance knowledge and multidisciplinary collaboration in the management of interstitial lung diseases (ILDs).

This year, the event recorded a total of 230 registered participants from across Malaysia, including nine delegates from Indonesia, reflecting growing regional interest and engagement.

The scientific program featured 19 speakers, comprising a strong representation of local faculty, complemented by two international virtual speakers, Prof. Kim Hyun Sook, Rheumatologist from South Korea, and Dr. Felix Chua from the United Kingdom.

Lectures covered a wide spectrum of ILD-related topics delivered by experts from various disciplines, including palliative medicine, cardiology, pathology, respiratory medicine, thoracic radiology, and physiotherapy. These sessions provided participants with valuable updates and practical insights into current approaches to diagnosis, management, and supportive care in ILD.

A highlight of the course was the **two multidisciplinary team (MDT) discussion sessions**, which reviewed several **challenging and interesting ILD cases**, encouraging interactive learning and collective problem-solving.

Another engaging segment was the **HRCT Quiz**, which tested participants' imaging interpretation skills. The **top five highest scorers** were awarded prizes for their outstanding performance.

The program also included an impactful patient sharing session, featuring one patient with Idiopathic Pulmonary Fibrosis (IPF) and another with Progressive Pulmonary Fibrosis (PPF) secondary to autoimmune ILD. Both patients shared their personal journeys from diagnosis to treatmen offering an inspiring perspective on living with fibrotic lung disease and coping with its challenges.

Overall, the **9th ILD Update 2025** was a resounding success, achieving its goal of advancing education, promoting multidisciplinary collaboration, and enhancing patient-centred care in ILD across Malaysia and the region.

Prepared by, Dr Syazatul Syakirin Sirol Aflah Group Leader Special Interest Group Interstitial Lung Disease